Pharmaceutical
Industry
Privately
held company engaged in the business of developing, testing and
commercializing topical pharmaceutical products. The company has
developed a portfolio of innovative and proprietary pharmaceutical
products to proceed to commercialization.
Financing
Sought: $13-15 million
Purpose:
To
commercialize business development and to perform research and development
activities to include formal, controlled double blind clinical trials for
several new medicines that can very effectively compete in large and
significantly growing markets through successful commercialization.
Completion of controlled clinical trials for these medicines will
facilitate early-stage licensing and/or co-development transactions with
established pharmaceutical companies.
Company's
Core Technology:
Patents
issued and patents pending. The company's chemical technology has
high product gross margins, maintains very low toxicity, and works by
improving immune system functioning where its new medications are applied,
resulting in successful treatment of certain diseases such as cervical
dysplasia (pre-cancerous conditions), herpes simplex and genital
warts. The technology uses generally regarded as safe (GRAS)
chemical substances to optimize the environment of the natural immune
response of mucosal, skin and wound surfaces. The new medications
incorporating this technology as well as the incorporation of in-licensed
technology provides both growth opportunities and increased
commercialization opportunities for the company.
Intellectual
Properties:
Company
has several completed, patented (US and International),
manufacturing-established new drugs that have worked very well in early
pilot human testing.
Laboratories
and Facilities:
Utilizes
laboratory and clinical facilities in multiple location in the US and
Internationally. Use of state of the art contract manufacturing
facilities.
Revenue
Expectation:
First
year revenue expectation of about $15M.
SUBMITTING CANDIDATE
OPPORTUNITIES
To discuss criteria further, or
to submit a candidate for consideration, please contact:
Diane C. Harris, President
Hypotenuse Enterprises, Inc.
1545 East Avenue
Rochester, N.Y. 14610 USA
E-mail: info@hypot.com
Voice: 585-473-7799
Fax: 585-473-7465
Neither Hypotenuse Enterprises, Inc. nor the
potential acquirer will be liable for any fees or expenses unless agreed in
writing between the parties. 